Leading the Future of Scientific Innovation
Event Recap : Revvity Signals NEXUS Europe 2025
August 5, 2025 Read Blog

Mary Donlan, Ph.D.
Executive Director, Product Marketing
Event Recap : Revvity Signals NEXUS Europe 2025
August 5, 2025 Read Blog
Executive Director, Product Marketing
Signals One unifies and structures data to be AI-ready. Our automation allows AI and machine-learning tools analyze data so that scientists can focus on innovation.
Artificial intelligence (AI) and machine learning (ML) are revolutionizing the cybersecurity space. Learn how Revvity Signals uses AI and other techniques to protect data.
Signals One™ has RNA specific tools for leading biopharmaceutical companies to make data-driven decisions. Learn how we meet chemists and RNA biologists needs.
This article highlights the critical role of an AI-ready data strategy in drug discovery, emphasizing that AI is only as effective as the quality of data it processes.
This article explores how AI and ML are revolutionizing drug discovery by enhancing data accessibility, automating chemical reaction recommendations, and improving cellular imaging.
Revvity Signal understands the opportunities that accompany creating the lab of the future. Our SaaS solutions helps businesses leverage modern technologies, including AI and ML.
This article discusses the role of digital tools like the Signals Research Suite in optimizing biosimilar development by streamlining data capture, analysis, and collaboration.
This article discusses how digital transformation is enhancing R&D efficiency in the pharmaceutical and chemical industries.
This article explores how Revvity Signals Solutions are transforming drug discovery by addressing inefficiencies in pharma and biotech workflows.
This article discusses the role of end-to-end R&D solutions in enhancing drug development efficiency by streamlining data capture, collaboration, and regulatory compliance.
The article discusses strategies for overcoming productivity challenges in chemical R&D by leveraging digital solutions.
Signals One unifies and structures data to be AI-ready. Our automation allows AI and machine-learning tools analyze data so that scientists can focus on innovation.
Modern drug discovery and biosimilar development projects generate very large volumes of data, yet results held in proprietary, legacy and device-dependent unstructured formats can limit access and lead to increased costs and lengthened delays. Help is at hand, with new AI solutions able to find, process, and summarize data from almost any source in near-real-time, transforming productivity.
This article discusses how integrating technologies like AI, machine learning, and data analytics can enhance drug development efficiency in India's pharmaceutical industry.